Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric study of BAX 855 in previously treated patients with severe hemophilia A
2014-000742-30Phase 3Terminated
- Sponsor
- Baxter International Inc.
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant coagulation factor viii in hemophilia A, sponsored by Baxter International Inc. Primary endpoint: Incidence of factor VIII inhibitory antibodies. Started May 2014; status: terminated.
02
Drugs
recombinant coagulation factor viii
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2014-000742-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000742-30.